Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema

• Status: Completed
• Trial end date: 1994-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To test the efficacy of acetazolamide for the treatment of uveitis-associated cystoid macular edema.

• Phase: Phase 2

Details

• Lead Sponsor: National Eye Institute (NEI)
• Treatments: Acetazolamide

Criteria

Males and females 8 years of age or older and weighing at least 35 kg (77 lb) were eligible for the study. Patients had to have a best corrected visual acuity of 20/40 or worse in at least one eye with cystoid macular edema demonstrable on fluorescein angiography.

Patients were allowed to receive systemic therapy for their uveitis. Exclusion criteria included current use of acetazolamide as part of a therapeutic regimen; a history of hypersensitivity reactions to acetazolamide, sulfonamides, or angiography dye; unclear ocular media that would obscure fluorescein angiography; macular subretinal neovascularization or a macular hole; or inability to take acetazolamide for medical reasons.